AffiliationChristie Hospital and Holt Radium Institute, WIlmslow Rd, Manchester M20 9BX
MetadataShow full item record
AbstractThe combination of trilostane 960 mg daily and either dexamethasone 0.5 mg b.d. or hydrocortisone 10 mg b.d. has been used to treat advanced metastatic breast cancer in post-menopausal women. Twenty-three patients had assessable disease and received treatment for a minimum of 8 weeks. Six (26%) showed an objective response and three (13%), stabilisation of previously progressive disease, sustained for at least 3 months. Side-effects were mainly gastrointestinal. Biochemical studies suggest that the mechanism of action may be inhibition of conversion of androstenedione to oestrone.
CitationTrilostane in the treatment of advanced breast cancer. 1983, 10 (3):158-60 Cancer Chemother Pharmacol
JournalCancer Chemotherapy and Pharmacology
- Trilostane with hydrocortisone in treatment of metastatic breast cancer.
- Authors: Chu PS, Buzdar AU, Hortobagyi GN
- Issue date: 1989 Mar
- Multicenter study of trilostane: a new hormonal agent in advanced postmenopausal breast cancer.
- Authors: Williams CJ, Barley V, Blackledge G, Hutcheon A, Kaye S, Smith D, Keen C, Webster DJ, Rowland C, Tyrrell C
- Issue date: 1987 Dec
- Evaluation of trilostane plus hydrocortisone in women with metastatic breast cancer and prior hormonal therapy exposure.
- Authors: Ingle JN, Krook JE, Schaid DJ, Everson LK, Mailliard JA, Long HJ, McCormack GW
- Issue date: 1990 Apr
- Hormonal changes in postmenopausal women with breast cancer treated with trilostane and dexamethasone.
- Authors: Beardwell CG, Hindley AC, Wilkinson PM, St John J, Bu'lock D
- Issue date: 1985 Oct
- Trilostane therapy for advanced breast cancer.
- Authors: Coombes RC, Powles TJ, Muindi J, Hunt J, Ward M, Perez D, Neville AM
- Issue date: 1985 Apr